Lozano-Calderon Santiago A, Colman Matthew W, Raskin Kevin A, Hornicek Francis J, Gebhardt Mark
Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA; Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA.
Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA; Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA.
Orthop Clin North Am. 2014 Jul;45(3):403-16. doi: 10.1016/j.ocl.2014.03.006.
Bisphosphonates are medications known to decrease bone resorption by inhibiting osteoclastic activity. They are the first-line therapy for the treatment of osteoporosis because a significant body of literature has proved their efficacy in reducing the risk of fracture in the hip, spine and other nonvertebral osseous sites. In addition, the use of bisphosphonates has significantly decreased morbidity and increased survival, and they have also proved to be cost-effective. Unexpected adverse effects have been reported recently, but the benefit of bisphosphonates use outweighs the risks. This article reviews the current use of bisphosphonates in orthopedic surgery.
双膦酸盐类药物是一类已知可通过抑制破骨细胞活性来减少骨吸收的药物。它们是治疗骨质疏松症的一线疗法，因为大量文献已证明其在降低髋部、脊柱和其他非椎体骨部位骨折风险方面的疗效。此外，双膦酸盐类药物的使用显著降低了发病率并提高了生存率，而且它们还被证明具有成本效益。最近有报道称出现了意外的不良反应，但使用双膦酸盐类药物的益处大于风险。本文综述了双膦酸盐类药物在骨科手术中的当前应用情况。
